Malik L, Lu D
Invest New Drugs. 2018; 37(3):519-523.
PMID: 30443782
DOI: 10.1007/s10637-018-0699-1.
Langrand-Escure J, Rivoirard R, Oriol M, Tinquaut F, Rancoule C, Chauvin F
PLoS One. 2017; 12(12):e0185536.
PMID: 29216190
PMC: 5720777.
DOI: 10.1371/journal.pone.0185536.
He X, Zhang Y, Ma Y, Zhou T, Zhang J, Hong S
Medicine (Baltimore). 2016; 95(31):e4176.
PMID: 27495021
PMC: 4979775.
DOI: 10.1097/MD.0000000000004176.
Ramcharan K, Lip G, Stonelake P, Blann A
Int J Colorectal Dis. 2015; 30(3):315-21.
PMID: 25598043
DOI: 10.1007/s00384-014-2116-3.
Ezzalfani M, Zohar S, Qin R, Mandrekar S, Le Deley M
Stat Med. 2013; 32(16):2728-46.
PMID: 23335156
PMC: 3813987.
DOI: 10.1002/sim.5737.
Interpreting clinical assays for histone deacetylase inhibitors.
Martinet N, Bertrand P
Cancer Manag Res. 2011; 3:117-41.
PMID: 21625397
PMC: 3101110.
DOI: 10.2147/CMR.S9661.
Current molecular imaging of spinal tumors in clinical practice.
Sandu N, Popperl G, Toubert M, Spiriev T, Arasho B, Orabi M
Mol Med. 2011; 17(3-4):308-16.
PMID: 21210073
PMC: 3060992.
DOI: 10.2119/molmed.2010.00218.
Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.
Costelloe C, Chuang H, Madewell J, Ueno N
J Cancer. 2010; 1:80-92.
PMID: 20842228
PMC: 2938069.
DOI: 10.7150/jca.1.80.
Pediatric phase I trial design using maximum target inhibition as the primary endpoint.
Meany H, Balis F, Aikin A, Whitcomb P, Murphy R, Steinberg S
J Natl Cancer Inst. 2010; 102(12):909-12.
PMID: 20460632
PMC: 2886096.
DOI: 10.1093/jnci/djq174.
The changing face of phase 1 cancer clinical trials: new challenges in study requirements.
Craft B, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S
Cancer. 2009; 115(8):1592-7.
PMID: 19165808
PMC: 2668727.
DOI: 10.1002/cncr.24171.
Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?.
Schaller B, Modo M, Buchfelder M
Mol Imaging Biol. 2007; 9(2):60-71.
PMID: 17203238
DOI: 10.1007/s11307-006-0069-9.
New target-based agents involve new clinical trial designs.
Bueno Muino C, Garcia-Saenz J, Tarruella S, Rodriguez Lajustica L, Diaz-Rubio E
Clin Transl Oncol. 2006; 8(8):581-7.
PMID: 16952846
DOI: 10.1007/s12094-006-0063-3.
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Cetina L, Candelaria M
Mol Cancer. 2005; 4(1):22.
PMID: 16001982
PMC: 1198251.
DOI: 10.1186/1476-4598-4-22.
